USD 324.0
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 343.65 Million EUR | 3.85% |
2022 | 330.9 Million EUR | 22.41% |
2021 | 270.33 Million EUR | 28.1% |
2020 | 211.03 Million EUR | 2.16% |
2019 | 206.58 Million EUR | 5.52% |
2018 | 195.77 Million EUR | 5.96% |
2017 | 184.75 Million EUR | -6.64% |
2016 | 197.9 Million EUR | 8.55% |
2015 | 182.31 Million EUR | 14.04% |
2014 | 159.87 Million EUR | 15.2% |
2013 | 138.77 Million EUR | 4.94% |
2012 | 132.23 Million EUR | 18.25% |
2011 | 111.83 Million EUR | 13.08% |
2010 | 98.89 Million EUR | 40.01% |
2009 | 70.63 Million EUR | 1.1% |
2008 | 69.86 Million EUR | 12.25% |
2007 | 62.24 Million EUR | 4.34% |
2006 | 59.64 Million EUR | 1.83% |
2005 | 58.57 Million EUR | 7.96% |
2004 | 54.25 Million EUR | -14.0% |
2003 | 63.08 Million EUR | -10.53% |
2002 | 70.5 Million EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 407.12 Million EUR | 18.47% |
2024 Q2 | 407.12 Million EUR | 0.0% |
2023 Q1 | 341.25 Million EUR | 3.13% |
2023 Q4 | 343.65 Million EUR | 1.18% |
2023 Q3 | 339.66 Million EUR | -0.47% |
2023 Q2 | 341.25 Million EUR | 0.0% |
2023 FY | 343.65 Million EUR | 3.85% |
2022 Q4 | 330.9 Million EUR | 0.0% |
2022 Q1 | 306.53 Million EUR | 13.39% |
2022 FY | 330.9 Million EUR | 22.41% |
2022 Q2 | 306.53 Million EUR | 0.0% |
2022 Q3 | 330.9 Million EUR | 7.95% |
2021 FY | 270.33 Million EUR | 28.1% |
2021 Q1 | 239.52 Million EUR | 13.5% |
2021 Q3 | 270.33 Million EUR | 12.86% |
2021 Q4 | 270.33 Million EUR | 0.0% |
2021 Q2 | 239.52 Million EUR | 0.0% |
2020 FY | 211.03 Million EUR | 2.16% |
2020 Q2 | 202.53 Million EUR | 0.0% |
2020 Q4 | 211.03 Million EUR | 0.0% |
2020 Q1 | 202.53 Million EUR | -1.96% |
2020 Q3 | 211.03 Million EUR | 4.2% |
2019 Q4 | 206.58 Million EUR | 0.0% |
2019 Q2 | 208.85 Million EUR | 0.0% |
2019 Q3 | 206.58 Million EUR | -1.09% |
2019 Q1 | 208.85 Million EUR | 6.68% |
2019 FY | 206.58 Million EUR | 5.52% |
2018 Q3 | 195.77 Million EUR | -0.72% |
2018 Q1 | 197.2 Million EUR | 6.74% |
2018 FY | 195.77 Million EUR | 5.96% |
2018 Q4 | 195.77 Million EUR | 0.0% |
2018 Q2 | 197.2 Million EUR | 0.0% |
2017 Q4 | 184.75 Million EUR | 0.0% |
2017 FY | 184.75 Million EUR | -6.64% |
2017 Q2 | 194.41 Million EUR | 0.0% |
2017 Q1 | 194.41 Million EUR | -1.77% |
2017 Q3 | 184.75 Million EUR | -4.97% |
2016 Q1 | 199.47 Million EUR | 9.41% |
2016 FY | 197.9 Million EUR | 8.55% |
2016 Q4 | 197.9 Million EUR | 0.0% |
2016 Q3 | 197.9 Million EUR | -0.79% |
2016 Q2 | 199.47 Million EUR | 0.0% |
2015 FY | 182.31 Million EUR | 14.04% |
2015 Q4 | 182.31 Million EUR | 0.0% |
2015 Q1 | 193.62 Million EUR | 21.11% |
2015 Q3 | 182.31 Million EUR | -5.84% |
2015 Q2 | 193.62 Million EUR | 0.0% |
2014 Q3 | 159.87 Million EUR | 2.02% |
2014 Q1 | 156.7 Million EUR | 12.92% |
2014 FY | 159.87 Million EUR | 15.2% |
2014 Q4 | 159.87 Million EUR | 0.0% |
2014 Q2 | 156.7 Million EUR | 0.0% |
2013 FY | 138.77 Million EUR | 4.94% |
2013 Q4 | 138.77 Million EUR | 0.0% |
2013 Q3 | 138.77 Million EUR | 1.0% |
2013 Q2 | 137.4 Million EUR | 0.0% |
2013 Q1 | 137.4 Million EUR | 3.91% |
2012 FY | 132.23 Million EUR | 18.25% |
2012 Q4 | 132.23 Million EUR | 0.0% |
2012 Q2 | 118.26 Million EUR | 0.0% |
2011 Q2 | 109.64 Million EUR | 0.0% |
2011 Q4 | 111.83 Million EUR | 0.0% |
2011 FY | 111.83 Million EUR | 13.08% |
2010 FY | 98.89 Million EUR | 40.01% |
2010 Q2 | 94.39 Million EUR | 0.0% |
2010 Q4 | 98.89 Million EUR | 0.0% |
2009 Q4 | 70.63 Million EUR | 0.0% |
2009 FY | 70.63 Million EUR | 1.1% |
2008 FY | 69.86 Million EUR | 12.25% |
2007 FY | 62.24 Million EUR | 4.34% |
2006 FY | 59.64 Million EUR | 1.83% |
2005 FY | 58.57 Million EUR | 7.96% |
2004 FY | 54.25 Million EUR | -14.0% |
2003 FY | 63.08 Million EUR | -10.53% |
2002 FY | 70.5 Million EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AstraZeneca PLC | 5.41 Billion USD | 93.655% |
Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | 87.09% |
CSPC Pharmaceutical Group Limited | 442.43 Million USD | 22.326% |
Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | -2317.722% |
Novartis AG | 5.91 Billion USD | 94.188% |
PT Kalbe Farma Tbk. | 451.27 Million USD | 23.849% |